01-06-2009 | Update
Update in Women’s Health
Published in: Journal of General Internal Medicine | Issue 6/2009
Login to get accessABSTRACT
INTRODUCTION
METHODS
RESULTS
Topic | Issuing organization | Updated recommendations and comments |
---|---|---|
Mammography screening in women 40–4917
| ACP | Individualized risk assessment and informed decision making should be used to guide decisions about mammography screening in this age group. |
To aid in the risk assessment, a discussion of the risk factors, which if present in a woman in her 40s increases her risk to above that of an average 50-year-old woman, is provided in the guidelines. In addition, available risk prediction models, such as the NIH Web site calculator (http://www.cancer.gov/bcrisktool/) can also be used to estimate quantitative breast cancer risk. This model was updated in 2008 with race-specific data for calculating risk in African-American women.18
| ||
The harms and benefits of mammography should be discussed and incorporated along with a woman’s preferences and breast cancer risk profile into the decision on when to begin screening. If a woman decides to forgo mammography, the decision should be readdressed every 1 to 2 years. | ||
STD screening guidelines19
| USPSTF and CDC | Routine screening for this infection is now recommended for ALL sexually active women age 24 and under, based on the recent high prevalence estimates for chlamydia |
It is not recommended for women (pregnant or nonpregnant) age 25 and older, unless they are at increased risk for infection. | ||
STD treatment guidelines20
| CDC | Flouroquinolones are NO longer recommended for treatment of N. gonorrhea, due to increasing resistance (as high as 15% of isolates in 2006). |
For uncomplicated infections, treatment of gonorrhea should be initiated with ceftriaxone 125 mg IM or cefixime 400 mg PO and co-treatment for chlamydia infection (unless ruled out with testing). Recent estimates demonstrate that almost 50% of persons with gonorrhea have concomitant chlamydia infection21. |